CN114425052B - Sildenafil for preparing pharmaceutical composition for treating ischemia and application thereof - Google Patents
Sildenafil for preparing pharmaceutical composition for treating ischemia and application thereof Download PDFInfo
- Publication number
- CN114425052B CN114425052B CN202011176804.9A CN202011176804A CN114425052B CN 114425052 B CN114425052 B CN 114425052B CN 202011176804 A CN202011176804 A CN 202011176804A CN 114425052 B CN114425052 B CN 114425052B
- Authority
- CN
- China
- Prior art keywords
- sildenafil
- pharmaceutical composition
- ischemia
- dose
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 title claims abstract description 104
- 208000028867 ischemia Diseases 0.000 title claims abstract description 62
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 58
- 229960003310 sildenafil Drugs 0.000 title claims abstract description 52
- 239000006071 cream Substances 0.000 claims abstract description 13
- 239000003937 drug carrier Substances 0.000 claims abstract description 12
- -1 polyoxypropylene Polymers 0.000 claims description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- 239000000499 gel Substances 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- 230000002028 premature Effects 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 239000004264 Petrolatum Substances 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 208000007502 anemia Diseases 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 235000019271 petrolatum Nutrition 0.000 claims description 5
- 229940066842 petrolatum Drugs 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 239000004166 Lanolin Substances 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 235000013871 bee wax Nutrition 0.000 claims description 4
- 239000012166 beeswax Substances 0.000 claims description 4
- 229940092738 beeswax Drugs 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000008387 emulsifying waxe Substances 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000002191 fatty alcohols Chemical class 0.000 claims description 4
- 150000002195 fatty ethers Chemical class 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 235000019388 lanolin Nutrition 0.000 claims description 4
- 229940039717 lanolin Drugs 0.000 claims description 4
- 239000002480 mineral oil Substances 0.000 claims description 4
- 235000010446 mineral oil Nutrition 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 239000004584 polyacrylic acid Substances 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 4
- 239000011118 polyvinyl acetate Substances 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 230000007954 hypoxia Effects 0.000 claims description 3
- 239000002674 ointment Substances 0.000 abstract description 10
- 239000002552 dosage form Substances 0.000 abstract description 5
- 210000001519 tissue Anatomy 0.000 description 26
- 230000000694 effects Effects 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 230000000302 ischemic effect Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 230000006872 improvement Effects 0.000 description 9
- 206010028851 Necrosis Diseases 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 201000002818 limb ischemia Diseases 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000017074 necrotic cell death Effects 0.000 description 8
- 231100000862 numbness Toxicity 0.000 description 8
- 230000036269 ulceration Effects 0.000 description 8
- 230000009471 action Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 229920002545 silicone oil Polymers 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 206010047163 Vasospasm Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000008338 local blood flow Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000036266 weeks of gestation Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 210000002659 acromion Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000008542 feiji Substances 0.000 description 1
- 210000000454 fifth toe Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 229910052611 pyroxene Inorganic materials 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 210000000453 second toe Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940048842 sodium xylenesulfonate Drugs 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to sildenafil for preparing a pharmaceutical composition for treating ischemia and application thereof. The invention discloses a pharmaceutical composition for treating ischemia, which is used for patients suffering from ischemia. The pharmaceutical composition comprises Sildenafil (Sildenafil) and a pharmaceutically acceptable carrier, wherein the dosage form of the pharmaceutical composition is gel, transdermal patch, cream or ointment. The invention further discloses application of sildenafil in preparing a pharmaceutical composition for treating ischemia. The application and the pharmaceutical composition can be used for treating ischemia.
Description
Technical Field
The invention relates to a pharmaceutical composition for treating ischemia and application of the pharmaceutical composition.
Background
Ischemia refers to a decrease in blood volume in an organ or tissue, which may be the result of a local manifestation of systemic anemia, or a local blood circulation disorder. Depending on the location where ischemia occurs, it may be classified as limb ischemia or organ ischemia, such as cerebral ischemia (ischemic stroke), cardiac ischemia (ischemic heart disease), and the like. In recent years, the incidence of peripheral arterial occlusive disease has increased due to aging of the population, smoking, changes in eating habits, and an increase in the proportion of the mouth of diabetics, and thus the incidence of limb ischemia has increased, and the prevalence may be even as high as 11%. In addition to peripheral arterial occlusive disease, raynaud's phenomenon, berger's disease, vasospasm, compression, etc. may also cause limb ischemia to occur.
Limb ischemia may also occur in newborns, especially premature infants. The cause of this is different from that of adults, and may be caused by hypoplasia, hypoxia, anemia, etc. However, ischemia of the limb, whether it is an adult or a neonate, may cause numbness, pain or ice-cooling of the limb end, and with increased ischemia time, may lead to purple, black, or even ulceration or necrosis of the tissue.
Traditionally, ischemia is treated primarily by oral medications, however, orally administered medications may act not only on the ischemic site, but also throughout the body. Therefore, systemic or systemic side effects may occur, and the speed and efficacy of the drug may be easily affected by organs (e.g., liver, kidney, etc.) that metabolize the drug.
Therefore, there is still a need for a pharmaceutical composition for treating ischemia and its preparation and application, which can directly act on ischemic tissues to promote blood circulation, so as to avoid numbness, pain, and even purple, black, ulceration or necrosis of the ischemic tissues caused by ischemia, further achieve the effect of treating ischemia, and further avoid side effects caused by drug action on other tissues.
Disclosure of Invention
In view of the above problems, an object of the present invention is to provide a pharmaceutical composition for treating ischemia and its preparation method and use, wherein the pharmaceutical composition can be directly applied to ischemic tissues to promote blood circulation, so as to prevent the local tissues from numbness, pain, ice-cooling, and even purple, black, ulceration and necrosis caused by ischemia, thereby achieving the effect of treating ischemia, and simultaneously preventing side effects caused by drug action on other tissues.
To achieve the above object, the present invention provides a pharmaceutical composition for treating ischemia, which is used for patients suffering from ischemia, the pharmaceutical composition comprises Sildenafil (Sildenafil) and a pharmaceutically acceptable carrier, wherein the dosage form of the pharmaceutical composition is gel, transdermal patch, cream or ointment.
To achieve the above objective, the present invention further provides a use of sildenafil for preparing a pharmaceutical composition for treating ischemia, wherein the pharmaceutical composition is for patients suffering from ischemia, the pharmaceutical composition comprises sildenafil and a pharmaceutically acceptable carrier, and the pharmaceutical composition is in the form of gel, transdermal patch, cream or ointment.
In one embodiment, the dose of sildenafil is between 0.3 mg/ml and 50 mg/ml.
In one embodiment, the dose of sildenafil is between 0.5 mg/ml and 30 mg/ml.
In one embodiment, the dose of sildenafil is between 0.3 mg/cm and 50 mg/cm.
In one embodiment, the dose of sildenafil is between 0.5 mg/cm and 30 mg/cm.
In one embodiment, the pharmaceutically acceptable carrier is mineral oil, propylene glycol, polyoxypropylene, emulsifying wax, glycerin, polyethylene glycol, fatty alcohols, fatty ethers, fatty acid esters, vegetable oils, silicone oils, petrolatum, lanolin, beeswax, hyaluronic acid, polyacrylic acid, polyvinylpyrrolidone, gelatin, dextrin, polysaccharides, polyacrylamide, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl methylcellulose, or carboxypropyl methylcellulose.
In one embodiment, the patient is a neonate, infant or young child.
In the above, the invention has the following effects: by providing the pharmaceutical composition for treating ischemia and the preparation and application thereof, the pharmaceutical composition can directly act on ischemic tissues to promote the blood circulation of the local tissues so as to prevent the local tissues from numbness, pain, even purple, blackening, ulceration or necrosis caused by ischemia, further achieve the effect of treating ischemia and further simultaneously prevent side effects caused by the action of drugs on other tissues.
Detailed Description
Preferred embodiments and experimental examples of the pharmaceutical composition for treating ischemia and the preparation use thereof according to the present invention will be described below with reference to the relevant tables, wherein like elements will be described with like reference numerals.
The pharmaceutical composition and the preparation and application thereof can directly act on ischemic tissues to promote the blood circulation of the local tissues, so as to avoid numbness and pain, and even purple, black, ulceration or necrosis of the local tissues caused by ischemia, further achieve the effect of treating the ischemia, and further avoid side effects caused by the action of medicines on other tissues.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the testing experiments of the present invention, the preferred materials and methods are described herein. In describing and claiming the present invention, the following terminology will be used. It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The term "ischemia" refers to a decrease in blood volume in an organ or tissue, which may be the result of a local manifestation of systemic anemia, or a local blood circulation disorder. Depending on the location where ischemia occurs, it may be classified as limb ischemia or organ ischemia, such as cerebral ischemia (ischemic stroke), cardiac ischemia (ischemic heart disease), and the like. Limb ischemia may be caused by peripheral arterial occlusive disease, raynaud's phenomenon, berger's disease, vasospasm, compression, hypoplasia, hypoxia, anemia, and the like. Limb ischemia may cause numbness, pain or ice-cold at the limb ends, and with the increase of ischemia time, limb purple, blackening, even tissue ulceration and necrosis are more likely to occur.
The term "Sildenafil" also known as "Sildenafil", which is a fifth phosphodiesterase inhibitor acting on phosphodiesterase 5 (PDE 5), which IUPAC name 1- [ 4-ethoxy-3- (6, 7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4,3d ]]Pyrimidin-5-yl) benzenesulfonyl]-4-methylpiperazine citrate in the form of a pharmaceutical product. Sildenafil is approved by the U.S. food and drug administration for the treatment of penile erectile dysfunction. The medicine is prepared by using the product name of pyroxene (Pfizer)It is sold as a film-coated lozenge containing 25, 50 or 100 mg sildenafil citrate. Sildenafil of the invention may have the following structure, or salts (e.g., citrate), solvates, hydrates, prodrugs, mirror isomers, non-mirror isomers, or geometric isomers thereof.
As used herein, "disease" in the health status of an individual refers to the inability of an individual to maintain a constant in vivo (homeostasis) and if the disease does not improve, the health of an individual continues to deteriorate.
As used herein, the terms "treatment", "treatment" and "treatment method" refer to reducing the frequency or severity of symptoms of a disease or disorder experienced by an individual by administering to the individual an agent or pharmaceutical composition.
As used herein, the term "pharmaceutically acceptable" refers to a material, such as a carrier or diluent, that is sildenafil, or a salt, solvate, hydrate, prodrug, enantiomer, non-enantiomer, or geometric isomer thereof, useful in the present invention, which retains its biological activity or properties and is relatively non-toxic. I.e. the material may be applied to an individual without causing undesirable biological effects or interacting in a detrimental manner with any of the ingredients contained in the composition.
As used herein, a "pharmaceutically acceptable carrier" includes salts, materials, compositions or carriers, such as fillers, diluents, excipients or encapsulating materials, that allow sildenafil of the present invention to be applied to a subject's body surface and allow sildenafil to perform its intended function. Each salt or carrier must be compatible with the other ingredients of the formulation, including sildenafil useful in the present invention, and not deleterious to the subject. Examples of materials that can be used as carriers include: sugars such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower seed oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; a diluent; granulating agent; a lubricant; an adhesive; a disintegrant; a wetting agent; an emulsifying agent; a colorant; a release agent; a coating agent; a fragrance; a preservative; an antioxidant; a plasticizer; a gelling agent; a thickener; a hardening agent; a setting agent; a surfactant; a humectant; a carrier; a stabilizer; and other non-toxic compatible materials used in the formulation, or any combination thereof.
The pharmaceutical compositions of the methods of the invention are suitable for topical or transdermal routes of administration. Suitable pharmaceutical compositions are in dosage forms such as, but not limited to, gels, emulsions, transdermal patches, creams, ointments (pastes).
Formulations suitable for topical application include, but are not limited to, liquid or semi-liquid formulations such as wipes, lotions, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes. Although the concentration of the active ingredient may be as high as the limit of solubility of the active ingredient in the solvent, a topically applied formulation may, for example, contain about 1% to about 10% (w/w) of the active ingredient. Formulations for topical application may further comprise one or more additional ingredients described herein.
The carrier in a gel, emulsion, transdermal patch, cream, ointment of a pharmaceutical composition that may be for topical or transdermal administration may be, for example, but not limited to, mineral oil, propylene glycol, polyoxypropylene, emulsifying wax, glycerin, polyethylene glycol, fatty alcohol, fatty ether, fatty acid ester, vegetable oil, silicone oil, petrolatum, lanolin, beeswax, hyaluronic acid, polyacrylic acid, polyvinylpyrrolidone, gelatin, dextrin, polysaccharide, polyacrylamide, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl methylcellulose, or carboxypropyl methylcellulose.
The topically applied pharmaceutical composition may optionally be combined with other ingredients such as adjuvants, antioxidants, chelating agents, surfactants, foaming agents, wetting agents, emulsifiers, viscosity enhancers, buffers, preservatives and the like. In other embodiments, penetration or permeation enhancers are included in the composition and are effective to improve transdermal penetration of the active ingredient into and through the stratum corneum relative to compositions lacking the penetration enhancers. Various permeation enhancers are known to those skilled in the art, including oleic acid, oleyl alcohol, ethoxydiglycol, laurocapram, alkenyl carboxylic acids, dimethyl sulfoxide, polar lipids or N-methyl-2-pyrrolidone. In another embodiment, the composition may further comprise a solubilizing agent that functions to increase the degree of turbulence of the stratum corneum structure, thereby enhancing transport across the stratum corneum. Various solubilizing agents known to those skilled in the art, such as isopropyl alcohol, propylene glycol or sodium xylene sulfonate.
The formulations of the pharmaceutical compositions described herein may be prepared by any method known or later developed in the pharmacological and pharmaceutical arts. Generally, such a preparation method comprises the following steps: the active ingredient is combined with a carrier or one or more other auxiliary ingredients, and the product is then formed or packaged, if desired or feasible, into the intended unit of single or multiple doses.
As used in this specification, "patient," "individual," "subject," and "subject" are used interchangeably and refer to a human or non-human mammal. Non-human mammals include, for example, domestic animals and pets, such as sheep, cattle, pigs, dogs, cats, and murine mammals. Preferably, the patient is a human.
The term "neonate" refers to a human within 28 days after birth. The term "infant" refers to a human between 28 days postnatal and 1 year old. The term "young child" refers to a human between 1 and 3 years of age. The term "premature infant" particularly refers to newborns born after 20 weeks of gestation but less than 37 weeks of gestation.
As used in this specification, "dose" means a dose of sildenafil that can promote blood circulation. In the gel, cream or ointment of the present invention, the dosage of sildenafil is between 0.3 mg/ml and 50 mg/ml. Preferably, the dose of sildenafil is between 0.5 mg/ml and 30 mg/ml. Preferably, the dose of sildenafil is between 1 mg/ml and 5 mg/ml. In the transdermal patch of the present invention, the dose of sildenafil is between 0.3 mg/cm and 50 mg/cm. Preferably, the dose of sildenafil is between 0.5 mg/cm and 30 mg/cm. Preferably, the dose of sildenafil is between 1 mg/square cm and 5 mg/square cm.
The range is as follows: various embodiments of the invention may be presented throughout the present disclosure in a range of forms. It should be understood that the description of the range format is merely for convenience and brevity and should not be interpreted as limiting the scope of the claims. Accordingly, the description of a range should be considered to specifically disclose all possible sub-ranges and single values within the range. For example, a description of a range from 1 to 6 should be considered to have the particular disclosed subranges, e.g., from 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as single and partial numbers within that range, e.g., 1, 2, 2.7, 3, 4, 5, 5.3, and 6. The foregoing rules apply regardless of the span of the range.
The invention relates to a pharmaceutical composition for treating ischemia, which is used for patients suffering from ischemia, and comprises Sildenafil (Sildenafil) and a pharmaceutically acceptable carrier, wherein the dosage form of the pharmaceutical composition is gel, transdermal patch, cream or ointment. In this embodiment, a dose of sildenafil may be withdrawn or weighed and a pharmaceutically acceptable carrier may be added to prepare a pharmaceutical composition for administration to the ischemic site of a patient to achieve the effect of promoting blood circulation at the site and thereby treat ischemia. In particular, sildenafil may have the following structure, or salts, solvates, hydrates, prodrugs, enantiomers, non-enantiomers or geometric isomers thereof, without limitation of the invention.
In addition, the pharmaceutical composition of the present invention includes a dosage form of gel, transdermal patch, cream or ointment. In this embodiment, when the pharmaceutical composition is in the form of a gel, cream or paste, the dosage of sildenafil is between 0.3 mg/ml and 50 mg/ml, preferably the dosage of sildenafil is between 0.5 mg/ml and 30 mg/ml. Preferably, the dose of sildenafil is between 1 mg/ml and 5 mg/ml. In this embodiment, when the pharmaceutical composition is in the form of a transdermal patch, the dosage of sildenafil is between 0.3 mg/cm and 50 mg/cm, preferably between 0.5 mg/cm and 30 mg/cm. Preferably, the dose of sildenafil is between 1 mg/square cm and 5 mg/square cm. Of course, the dosage of sildenafil can be any number and range encompassed between any two of the foregoing ranges and can vary with the carrier in question, the route of administration, or the individual in need thereof and with respect to physiological conditions.
In this embodiment, the pharmaceutically acceptable carrier is mineral oil, propylene glycol, polyoxypropylene, emulsifying wax, glycerin, polyethylene glycol, fatty alcohol, fatty ether, fatty acid ester, vegetable oil, silicone oil, petrolatum, lanolin, beeswax, hyaluronic acid, polyacrylic acid, polyvinylpyrrolidone, gelatin, dextrin, polysaccharide, polyacrylamide, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl methylcellulose, or carboxypropyl methylcellulose. Preferably, the pharmaceutically acceptable carrier is petrolatum.
In this embodiment, the ischemia is limb ischemia, also referred to as acroischemia or terminal ischemia, such as, but not limited to, chronic acroischemia or acute acroischemia.
In this embodiment, the patient is a neonate, infant or young child. Preferably, the patient is a premature infant in the neonate.
The invention further provides a use of Sildenafil (Sildenafil) for preparing a pharmaceutical composition for treating ischemia. In addition, the present invention provides a method for treating ischemia, comprising administering a pharmaceutical composition comprising Sildenafil (Sildenafil) and a pharmaceutically acceptable carrier to an affected area of a patient suffering from ischemia, the pharmaceutical composition being in the form of a gel, transdermal patch, cream or ointment, the ischemia being acroischemia, and the patient being a premature infant. However, the dosage, type of carrier, and other properties of the pharmaceutical composition are substantially the same as those of the pharmaceutical composition described above, and reference is made to the above description, and thus, the description thereof will not be repeated.
In the above, the pharmaceutical composition and the preparation and application thereof according to the invention can directly act on ischemic tissues to promote the blood circulation of the local tissues, so as to avoid numbness, pain, even purple, blackening, ulceration or necrosis of the local tissues caused by ischemia, further achieve the effect of treating ischemia, and further avoid side effects caused by the action of drugs on other tissues.
The following experimental examples are used to illustrate the use and pharmaceutical compositions of the present invention, providing significant efficacy for improving the therapeutic effects of acroischemia.
Experimental example one: preparing a pharmaceutical composition.
Sildenafil (trade nameOr->The pharmaceutical company of the large-size pharmaceutical company of the feiji) was mixed with 1 ml of a Sterile gel (a patient lubricant (sterilization), CEYOTEKPatient lubricant (Sterile), the company of the Asahi-yu technology, to prepare a pharmaceutical composition having a sildenafil dose of 1 mg/ml to 5 mg/ml for the subsequent experiment of experiment example two.
Experimental example two: sildenafil can improve the results of studies on symptoms of premature infant acroischemia.
Patient engaged in
Patients were from taiwan new light medical community legal new light Wu Huoshi commemorative hospital on premature infants treated from month 6 2018 to month 12 2018 who had acroischemia. The premature patients who conducted the experiment were all signed by their parents or legal agency of written informed consent approved by the research operation ethical norms review team (Institutional Review Board, IRB) of the hospital.
Table 1: patient status and treatment information
Therapeutic methods using the pharmaceutical compositions of the invention
The pharmaceutical composition prepared in experimental example one was applied to ischemic sites (affected parts) of patient 1 and patient 2. The application thickness is about 1mm, and the application area is changed according to the area of the affected part, and the affected part is required to be completely covered. After application, a gauze layer is covered and the application is performed for 30 minutes to allow the pharmaceutical composition to be absorbed by the affected area. And then removing the gauze and applying the medical composition, covering a new gauze layer, and standing for 30 minutes (without warm compress), wherein the steps are one treatment course. Repeating the treatment course: applying the medicinal composition, covering a layer of gauze, performing warm application for 30 min, removing the gauze, applying the medicinal composition, covering a layer of new gauze, standing for 30 min (no warm application), recording the improved state when the ischemia condition of the affected part is obviously improved, and continuing the treatment until the affected part is completely cured. The conditions of the affected area when ischemia occurred in the patient and the conditions of the affected area when symptom improvement was observed are shown in tables 2 and 3 below.
Table 2: the condition of the affected part when ischemia occurs in patient 1 and the condition of the affected part when symptom improvement is observed
Table 3: condition of affected part when ischemia occurs in patient 2 and condition of affected part when symptom improvement is observed
Please refer to both table 1 and table 2 for explaining the treatment condition of patient 1. As shown in table 1, patient 1 developed ischemia symptoms at 12 th day after birth, and after treatment with the pharmaceutical composition of the present invention for 2 hours, an improvement in symptoms was observed, and the affected area when ischemia was developed and the affected area when symptom improvement was observed (after treatment for 2 hours, i.e., 2 courses of treatment) are shown in table 2. As shown in table 2, the affected area at the time of symptom improvement was observed to be significantly smaller than that at the time of ischemia (before treatment), and the purple condition caused by ischemia was also observed to be improved (purple fade) in the second toe, even the fifth toe was observed to have been healed after 2 hours of treatment (2 courses of treatment). In addition, patient 1 had a complete cure time for ischemic symptoms of 3 days (see treatment period of table 1).
Please refer to both table 1 and table 3 for explaining the treatment condition of patient 2. As shown in table 1, patient 2 developed ischemia symptoms at 10 days after birth, and after treatment with the pharmaceutical composition of the present invention for 9 hours, an improvement in symptoms was observed, and the affected area when ischemia occurred and the affected area when symptom improvement was observed (after treatment for 9 hours, i.e., 9 courses of treatment) are shown in table 3. As shown in table 3, it was observed that the affected area at the time of symptom improvement was significantly smaller than that at the time of ischemia (before treatment), and the purple state due to ischemia was also improved (purple fade). In addition, patient 2 had a complete cure of ischemic symptoms for 8 days (see treatment period of table 1).
According to the results of the above experimental examples, it is shown that the pharmaceutical composition of the present invention can improve, even cure, the condition of premature infant acromion (toe) ischemia. In particular, although the above experimental example is described by taking the example of treating the ischemia of the extremity of the premature infant, the pharmaceutical composition and the preparation use thereof of the present invention can be used for the neonate, infant or infant of the non-premature infant, even other patients, the present invention is not limited thereto, and the treated part can be used for other parts, such as but not limited to fingers, arms, lower legs, thighs, etc. In addition, the carriers used in the pharmaceutical compositions of the above experimental examples are exemplified by gels, however, the pharmaceutical compositions may also include the carriers described in other parts herein, and are not limited thereto.
In summary, the pharmaceutical composition and the preparation and application thereof can directly act on ischemic tissues to promote blood circulation of the local tissues, so as to prevent numbness and pain, even purple, black, ulceration or necrosis of the local tissues caused by ischemia, further achieve the effect of treating ischemia, and further prevent side effects caused by drug action on other tissues.
The foregoing is by way of example only and is not limiting. Any equivalent modifications or variations to the present invention without departing from the spirit and scope of the present invention are intended to be included within the scope of the claims of the present application.
Claims (4)
1. Use of sildenafil for the preparation of a pharmaceutical composition for the treatment of ischemia due to hypoplasia, hypoxia, anaemia in a premature infant, characterized in that the pharmaceutical composition consists of sildenafil and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is in the form of a gel, a transdermal patch, a cream or a paste, and in the gel, cream or paste the dose of sildenafil is between 0.3 mg/ml and 50 mg/ml, and in the transdermal patch the dose of sildenafil is between 0.3 mg/cm and 50 mg/cm.
2. The use of claim 1, wherein the dose of sildenafil is between 0.5 mg/ml and 30 mg/ml.
3. The use of claim 1, wherein the dose of sildenafil is between 0.5 mg/square centimeter and 30 mg/square centimeter.
4. The use according to claim 1, wherein the pharmaceutically acceptable carrier is mineral oil, propylene glycol, polyoxypropylene, emulsifying wax, glycerin, polyethylene glycol, fatty alcohols, fatty ethers, fatty acid esters, petrolatum, lanolin, beeswax, hyaluronic acid, polyacrylic acid, polyvinylpyrrolidone, gelatin, dextrin, polyacrylamide, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl methylcellulose or carboxypropylmethylcellulose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011176804.9A CN114425052B (en) | 2020-10-29 | 2020-10-29 | Sildenafil for preparing pharmaceutical composition for treating ischemia and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011176804.9A CN114425052B (en) | 2020-10-29 | 2020-10-29 | Sildenafil for preparing pharmaceutical composition for treating ischemia and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114425052A CN114425052A (en) | 2022-05-03 |
| CN114425052B true CN114425052B (en) | 2024-03-22 |
Family
ID=81309861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011176804.9A Active CN114425052B (en) | 2020-10-29 | 2020-10-29 | Sildenafil for preparing pharmaceutical composition for treating ischemia and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114425052B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1552348A (en) * | 2003-05-30 | 2004-12-08 | 上海华拓医药科技发展有限公司 | Sedinafine composition and its use |
| RU2010146997A (en) * | 2010-11-17 | 2012-05-27 | Леонид Леонидович Клопотенко (RU) | PHARMACEUTICAL COMPOSITION CONTAINING SILDENAFIL AND / OR ALPROSTADIL, MINOXIDIL AND / OR EUFILLIN, TESTOSTERON AND / OR YOCHIMBIN AND LIPOSOMES FOR LOCAL USE |
-
2020
- 2020-10-29 CN CN202011176804.9A patent/CN114425052B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1552348A (en) * | 2003-05-30 | 2004-12-08 | 上海华拓医药科技发展有限公司 | Sedinafine composition and its use |
| RU2010146997A (en) * | 2010-11-17 | 2012-05-27 | Леонид Леонидович Клопотенко (RU) | PHARMACEUTICAL COMPOSITION CONTAINING SILDENAFIL AND / OR ALPROSTADIL, MINOXIDIL AND / OR EUFILLIN, TESTOSTERON AND / OR YOCHIMBIN AND LIPOSOMES FOR LOCAL USE |
Non-Patent Citations (3)
| Title |
|---|
| Protection of sildenafil citrate hydrogel against radiation-induced skin wounds;Shweta Kulshrestha;[J] Burns.;第46卷(第5期);1157-1169 * |
| 李力.小剂量西地那非联合贝前列素治疗结缔组织病伴雷诺综合征效果观察.临床误诊误治.2016,第29卷(第6期),69-71. * |
| 西地那非通过PKG 依赖通道诱导局部缺血组织血管再生;王涛;Chinese Journal of Andrology;第22卷(第1期);72 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114425052A (en) | 2022-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kunzi‐Rapp | Topical propranolol therapy for infantile hemangiomas | |
| DE3779999T2 (en) | INCREASE IN PENETRATION CAPABILITY BY MEANS OF A SUBSTANCE AND SHORT-CHAIN ALCOHOLIC SYSTEM CONTAINING CHANGES IN THE CELL HELL. | |
| JP2011500779A (en) | New formulation | |
| US20070196325A1 (en) | Compositions and methods for dermally treating infections | |
| CN115300508A (en) | Topical formulations comprising montelukast in combination with mussel adhesive protein | |
| EP1872788A1 (en) | External agent for treating wound | |
| JPS60152413A (en) | Composition for local application with improved percutaneousdrug release by menthol | |
| KR20200052934A (en) | Transdermal preparations | |
| PT1957040E (en) | Benzimidazole non-aqueous compositions | |
| CN114425052B (en) | Sildenafil for preparing pharmaceutical composition for treating ischemia and application thereof | |
| CN112770765B (en) | Composition for preventing and/or treating urogenital mucosa | |
| TWI724499B (en) | Pharmaceutical composition and use for applying sildenafil in ischemia treatment | |
| JP2010511723A (en) | Topical pharmaceutical composition | |
| KR101433396B1 (en) | Linseed extract medicament for application to the eye | |
| TWI776093B (en) | Use of ginkgo extracts for preparing a pharmaceutical composition for treating ischemia | |
| US11135256B2 (en) | Pharmaceutical composition and use thereof for ischemia treatment | |
| WO2012084978A1 (en) | (r)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases | |
| EP3675814A1 (en) | Composition for topical treatment of non-microorganism-caused inflammatory skin and mucous-membrane diseases | |
| JPH0940563A (en) | Composition for treating bed sore and skin ulcer | |
| EP2046310B1 (en) | Treatment and prevention of excessive scarring | |
| RU2359691C1 (en) | Agent and hygienic product for hemorrhoids and abirritation preventive maintenance | |
| US20150071880A1 (en) | Treatment of epithelial layer lesions | |
| US20210077494A1 (en) | Pharmaceutical composition and use thereof for ischemia treatment | |
| EA032200B1 (en) | Topical formulation of heparin | |
| EP0119852A1 (en) | Podophyllotoxin preparations for use in the treatment of genital warts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |